Current Articles
2026, Volume 46, Issue 8
Display Method:
2026,
44(8):
383-388, 425.
doi: 10.12206/j.issn.2097-2024.202411043
Abstract:
Oxidative stress is an important pathophysiological pathway for the development and progression of ferroptosis. Under pathological conditions, the production of a large amount of reactive oxygen species （ROS） exceeds the buffering capacity of the antioxidant defense system, resulting in lipid peroxidation and cell ferroptosis in the state of oxidative stress. Cellular lipid peroxidation can generate toxic aldehydes, which interact with important biological macromolecules and break the normal function of cells. At present, it has been found that aldehyde dehydrogenase 2 （ALDH2） can eliminate these aldehydes and regulate the cycle of toxic aldehydes-ROS-oxidative stress-lipid peroxidation, thereby improving the prognosis of diseases associated with iron death. Ferroptosis and ALDH2 were introduced, and the current researches on ALDH2 were summarized to improve diseases associated with iron death, which can open up new directions for the subsequent research on the treatment of diseases associated with iron death.
Oxidative stress is an important pathophysiological pathway for the development and progression of ferroptosis. Under pathological conditions, the production of a large amount of reactive oxygen species （ROS） exceeds the buffering capacity of the antioxidant defense system, resulting in lipid peroxidation and cell ferroptosis in the state of oxidative stress. Cellular lipid peroxidation can generate toxic aldehydes, which interact with important biological macromolecules and break the normal function of cells. At present, it has been found that aldehyde dehydrogenase 2 （ALDH2） can eliminate these aldehydes and regulate the cycle of toxic aldehydes-ROS-oxidative stress-lipid peroxidation, thereby improving the prognosis of diseases associated with iron death. Ferroptosis and ALDH2 were introduced, and the current researches on ALDH2 were summarized to improve diseases associated with iron death, which can open up new directions for the subsequent research on the treatment of diseases associated with iron death.
2026,
44(8):
389-394.
doi: 10.12206/j.issn.2097-2024.202509037
Abstract:
Oral vaccines, owing to their non-invasive nature, ease of administration, and ability to elicit both mucosal and systemic immune responses, represent a pivotal direction in vaccine development. Microfold cells （M cells）, a specialized subset of immune-surveillance epithelial cells, though sparsely distributed, possess exceptional capacity for antigen uptake and transcytosis, rendering them a critical target for overcoming the bottlenecks of oral vaccine delivery. The morphological structure, antigen uptake mechanisms, and surface receptor characteristics of intestinal M cells were summarized in this paper. The multifaceted challenges currently impeding M cell-targeted oral delivery and recent advances in targeting strategies based on receptor–ligand specific recognition were analyzed. The design and application of delivery carriers tailored for M cell targeting were reviewed, which aimed to provide insights and guidance for future research and development of M cell-targeted mucosal delivery systems in the intestine.
Oral vaccines, owing to their non-invasive nature, ease of administration, and ability to elicit both mucosal and systemic immune responses, represent a pivotal direction in vaccine development. Microfold cells （M cells）, a specialized subset of immune-surveillance epithelial cells, though sparsely distributed, possess exceptional capacity for antigen uptake and transcytosis, rendering them a critical target for overcoming the bottlenecks of oral vaccine delivery. The morphological structure, antigen uptake mechanisms, and surface receptor characteristics of intestinal M cells were summarized in this paper. The multifaceted challenges currently impeding M cell-targeted oral delivery and recent advances in targeting strategies based on receptor–ligand specific recognition were analyzed. The design and application of delivery carriers tailored for M cell targeting were reviewed, which aimed to provide insights and guidance for future research and development of M cell-targeted mucosal delivery systems in the intestine.
2026,
44(8):
395-399, 407.
doi: 10.12206/j.issn.2097-2024.202412058
Abstract:
Perilla leaf volatile oil is rich in monoterpenes, aromatic compounds, and other active constituents, with perillaldehyde as its characteristic marker, exhibiting a wide range of pharmacological activities including antibacterial, anti-inflammatory, and antitumor effects. In recent years, systematic studies have been conducted on its chemical composition and pharmacodynamic basis. The methods for content determination have become increasingly sophisticated, with gas chromatography-mass spectrometry (GC-MS) and other techniques being widely applied for comparative analysis of samples from different sources; however, the results are influenced by multiple factors such as germplasm variation, growth stage, and extraction process. Regarding the biosynthetic pathway, key enzyme genes involved in the mevalonate and shikimate pathways are being progressively elucidated. In terms of bioactivity, in vivo and in vitro experiments have confirmed that its volatile oil components exert synergistic effects through multi-target mechanisms, with applications extended to food preservation, flavor and fragrance industry, and pharmaceutical field. The research progress on the biosynthesis, content determination, and bioactivities of volatile oil components from perilla leaves was reviewed, aiming to further clarify the active material basis and mechanisms of action, and to provide a reference for more in-depth exploration and utilization of the medicinal and edible value of Perilla frutescens.
Perilla leaf volatile oil is rich in monoterpenes, aromatic compounds, and other active constituents, with perillaldehyde as its characteristic marker, exhibiting a wide range of pharmacological activities including antibacterial, anti-inflammatory, and antitumor effects. In recent years, systematic studies have been conducted on its chemical composition and pharmacodynamic basis. The methods for content determination have become increasingly sophisticated, with gas chromatography-mass spectrometry (GC-MS) and other techniques being widely applied for comparative analysis of samples from different sources; however, the results are influenced by multiple factors such as germplasm variation, growth stage, and extraction process. Regarding the biosynthetic pathway, key enzyme genes involved in the mevalonate and shikimate pathways are being progressively elucidated. In terms of bioactivity, in vivo and in vitro experiments have confirmed that its volatile oil components exert synergistic effects through multi-target mechanisms, with applications extended to food preservation, flavor and fragrance industry, and pharmaceutical field. The research progress on the biosynthesis, content determination, and bioactivities of volatile oil components from perilla leaves was reviewed, aiming to further clarify the active material basis and mechanisms of action, and to provide a reference for more in-depth exploration and utilization of the medicinal and edible value of Perilla frutescens.
2026,
44(8):
400-407.
doi: 10.12206/j.issn.2097-2024.202409045
Abstract:
Objective To investigate the effect of activating α7 nicotinic acetylcholine receptor （α7nAChR） on calcium chloride （CaCl2）-induced abdominal aortic aneurysm （AAA） injury in mice. Methods AAA model was induced by CaCl2 in wild type （WT） mice and α7nAChR knockout （α7nAChR−/−） mice. The effects of knockout of α7nAChR on histological damage in CaCl2-induced AAA mice and expression of inflammatory factors were assessed by HE staining, Elasticavan Gieson （EVG） staining and IHC staining. Rat-derived primary vascular smooth muscle cells （VSMC） were stimulated with tumor necrosis factor-α （TNF-α）, which mimicked the inflammatory environment of AAA. The expressions of inflammation-related proteins were detected by using Western-blot （WB） with or without PNU-282987 to activate α7nAChR. Results Aortic dilatation was obvious, and the aortic structure was disrupted in CaCl2-induced AAA mice. Knockout of α7nAChR further exacerbated the histological injury and significantly up-regulated the expression of inflammation-related proteins in aorta of AAA mice. It was showed that TNF-α stimulation of VSMC increased inflammation-related protein expression, whereas activation of α7nAChR prevented the phenomenon. Conclusion Activation of α7nAChR could attenuate CaCl2-induced AAA injury in mice by suppressing the inflammatory response.
2026,
44(8):
408-416, 430.
doi: 10.12206/j.issn.2097-2024.202405056
Abstract:
Objective To explore the mechanism of Shen Hong capsule in preventing and treating acute mountain sickness based on biological information platform and in vitro experiment. Methods Traditional Chinese Medicine Systems Pharmacology （TCMSP） and Traditional Chinese Medicine Information Database （TCMID） were used to obtain the active components and predicted targets of Shen Hong capsule. Therapeutic Target Database （TTD）, Disease Gene Network （DisGeNET） database and GeneCards database were used to search for the targets of acute mountain sickness related diseases, and the potential therapeutic targets were obtained. The protein-protein interaction （PPI） was analyzed by Search Tool for the Retrieval of Interacting Genes/Proteins （STRING）, the Database for Annotation, Visualization, and Integrated Discovery （DAVID） online platform was used to analyse the Gene Ontology （GO） and the Kyoto Encyclopedia of Genes and Genomes （KEGG） signal pathway enrichment. The network information was visualized by Cytoscape software, the key targets in PPI network were obtained according to the topology data, and the binding ability of main active components and key therapeutic targets were analyzed by molecular docking. The validation of the main active components was performed by liquid chromatography-mass spectrometry （LC-MS）. The hypoxia model was created by H9c2 cells, apoptosis was visualized by Hoechst33342 staining, and key target proteins were verified by Western blot. Results 91 active components, 3 main active components and 150 predicted targets were selected from Shen Hong capsule. 515 targets of altitude sickness-related diseases and 37 targets of Shen Hong capsule regulating altitude sickness-related diseases were screened out. 44 related signal pathways, such as HIF-1 signal pathway, PPAR signal pathway, drug metabolism - cytochrome P450, were enriched and analyzed. TNF, IL1B, VEGFA, NOS3, EGFR, ESR1, PPARG, NR3C1, HMOX1 and IFNG were 10 key targets. The molecular docking results showed that the docking conformations between the main active components and the key targets were stable. The three main active components of quercetin, luteolin and kaempferol were identified by LC-MS, and in vitro experiments proved that Shen Hong capsule could relieve acute hypoxia injury by regulating the expression of HIF-1α, PPARG, NOS3, and TNF. Conclusion Shen Hong capsule could regulate the body’s hypoxia response and metabolism through multi-component, multi-target and multi-channel ways, so as to prevent and treat acute mountain sickness. This study provided a direction for further exploring the mechanism of Shen Hong capsule, and also provided a theoretical basis for further development and clinical application.
2026,
44(8):
417-425.
doi: 10.12206/j.issn.2097-2024.202412022
Abstract:
Objective To investigate the potential protective mechanism of tanshinone ⅡA against acetaminophen （APAP）-induced acute liver injury. Methods Thirty mice were randomly divided into the normal group, model group, low-dose tanshinone ⅡA group （5 mg/kg）, medium-dose tanshinone ⅡA group （10 mg/kg） and high-dose tanshinone ⅡA group （20 mg/kg）. All groups were intragastrically administered once daily for 7 consecutive days. On the 7th day, except for the normal group, mice in the remaining groups were intraperitoneally injected with 400 mg/kg APAP to establish the acute lung injury （ALI） model. The protective effect of tanshinone ⅡA was evaluated based on the liver weight ratio, the levels of aspartate aminotransferase （AST） and alanine aminotransferase （ALT）, and HE staining. Targets of tanshinone ⅡA were predicted by the Traditional Chinese Medicine Systems Pharmacology （TCMSP）, and a shared target protein-protein interaction （PPI） network was constructed by Search Tool for the Retrieval of Interacting Genes/Proteins （STRING） 11.5 in combination with disease targets from GeneCards. The Gene Ontology （GO） and Kyoto Encyclopedia of Genes and Genomes （KEGG） enrichment analysis was performed by Database for Annotation, Visualization and Integrated Discovery （DAVID）, and the component-target-pathway network was constructed. The molecular docking between tanshinone ⅡA and the core targets was performed by AutoDock and visualised. Results Compared with the normal group, the liver weight ratio and serum aminotransferase level of mice with acute liver injury were significantly elevated （P<0.05）, and the pathological injury of liver tissue was obvious. After tanshinone ⅡA treatment, the above index were significantly reduced （P<0.05）, and the pathological injury was significantly improved. Further network pharmacological analysis was carried out and found that KEGG pathway enrichment analysis focused on IL-17 signaling pathway and tumor necrosis factor （TNF） signaling pathway, etc. In addition, the PPI core network showed that the key targets of tanshinone ⅡA to ameliorate acute liver injury mainly included TP53, AKT1, SRC, TNF and JUN. The molecular docking results showed that tanshinone ⅡA had high binding scores with the targets of MMP9, NFKB1, TNF, EP300 and SMAD3; and was able to bind to the targets of TP53, AKT1, SRC and JUN. Conclusion Tanshinone ⅡA may play a protective role against acute liver injury by regulating genes such as AKT1, JUN and TNF, and participating in signaling pathways such as TNF and IL-17.
2026,
44(8):
426-430.
doi: 10.12206/j.issn.2097-2024.202411036
Abstract:
Objective To evaluate the effect of remimazolam premedication on emergence delirium （ED） in children undergoing tonsillectomy and/or adenoidectomy. Methods Children aged 3-6 years who underwent tonsillectomy and/or adenoidectomy with general anesthesia in Zhongshan Hospital Affiliated to Xiamen University from July 2023 to September 2024 were randomly divided into 0.1 mg/kg remimazolam group （group R1）, 0.2 mg/kg remimazolam group group R2） and normal saline group （group P）. Three groups were sedated preoperatively with remimazolam 0.1 mg/kg, remimazolam 0.2 mg/kg and normal saline, respectively. The primary outcome was the incidence of ED. The secondary outcomes included the parental separation anxiety scale （PSAS） score when entering the operating room, the induction compliance checklist （ICC） score at induction, the anesthetic recovery time, the incidence of rescue propofol for ED, the face, legs, activity, cry, and consolability （FLACC） score and the incidence of postoperative pain during the recovery period, the incidence of adverse reactions during the operation and postoperatively, and the incidence of negative postoperative behavioral changes （NPOBCs） at first day, 7th day, 30th day postoperatively. Results A total of 119 children completed the study, including 41 children in group R1, 38 children in group R2, and 40 children ingroup P. The incidence of ED and propofol rescue, the PSAS scores and ICC scores of group R1 and R2 were lower than that of group P （P<0.05）, and the above results in group R2 was better than those in group R1 （P<0.05）. The FLACC score, the incidence of postoperative pain, and the incidence of adverse reactions among the three groups had no difference （P>0.05）. The incidence of NPOBCs at 1st day and 7th day postoperatively in group R1 and group R2 was lower than that in group P （P<0.05）, but no difference was detected at 30th day postoperatively among the three groups （P>0.05）. Conclusion Remimazolam used for preoperative sedation could reduce the incidence of ED in children undergoing tonsillectomy and/or adenoidectomy, and had a positive effect on alleviating the preoperative anxiety and preventing NPOBCs.
2026,
44(8):
431-436.
doi: 10.12206/j.issn.2097-2024.202601017
Abstract:
Objective To evaluate the cost-utility of risdiplam in the treatment of pediatric spinal muscular atrophy （SMA） and analyze changes in patients’ out-of-pocket economic burden under the medical insurance scenarios. Methods A Markov model was developed from the healthcare system perspective to compare the long-term costs and quality-adjusted life years （QALYs） of risdiplam treatment versus conventional therapy. The incremental cost-utility ratio （ICUR） was calculated. One-way sensitivity analysis and probabilistic sensitivity analysis were conducted to assess the robustness of the model. On this basis, health insurance scenarios were simulated to evaluate patients’ individual economic burden. Results Base-case analysis showed that risdiplam treatment generated additional health benefits but substantially increased medical costs. The resulting ICUR did not demonstrate a clear cost-utility advantage under the current willingness-to-pay threshold. Sensitivity analyses indicated that the model results were relatively robust, with drug costs and key utility parameters being the main drivers of economic outcomes. Health insurance scenario analysis demonstrated that increasing reimbursement levels and reducing patient copayment rates could significantly alleviate patients’ financial burden. Conclusion Risdiplam for pediatric SMA faces economic challenges under the current health insurance payment framework in China. However, optimizing health insurance reimbursement policies and developing multi-tiered healthcare security mechanisms may improve its affordability and accessibility.
Contribution System
Author Login
Review Login
Editor Login
Reader Login
News